/LBPH

LBPH Stock - Longboard Pharmaceuticals, Inc.

Q: What is the analyst price target for LBPH?

Analyst price target information is not currently available for LBPH.

Q: What is LBPH's market cap?

Market capitalization information is not currently available for LBPH.

Healthcare|Biotechnology|NASDAQ

$59.98+0.00%

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-8.7%upside

Target: $54.76

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for LBPH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.09

52W High$59.98

52W Low$59.98

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A
Gross Profit	$-5,000	$-5,000	$-1,000	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-56,759,000	$-44,798,000	$-27,839,000	$-14,400,000
Net Income	$-54,422,000	$-43,092,000	$-27,733,000	$-14,400,000
Net Margin	N/A	N/A	N/A	N/A
EPS	$-2.39	$-2.51	$-1.62	$-0.82

Company Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

4 Bullish0 Neutral/Bearish

Price Targets

$46

Average Target

↓ 23.9% Downside

Now

$13

Low

$46

Average

$90

High

Based on 6 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 10th 2024	Truist	Initiation	Buy	$60
July 1st 2024	Cantor Fitzgerald	Reiterated	Overweight	$90← $60
May 1st 2024	Robert W. Baird	Initiation	Outperform	$36
February 16th 2024	Citigroup	Initiation	Buy	$40
October 24th 2023	Cantor Fitzgerald	Resumed	Overweight	$35← $16
April 27th 2023	B. Riley Securities	Initiation	Buy	$13

Earnings History & Surprises

LBPH

Beat Rate

40%

Last 15 quarters

Avg Surprise

-1.6%

EPS vs Estimate

Beats / Misses

6/9

Last 12 quarters

Latest EPS

$-0.63

Q4 2024

EPS Surprise History

Q1 23

-4.8%

$-0.66vs$-0.63

Q2 23

+5.1%

$-0.56vs$-0.59

Q3 23

-6.6%

$-0.65vs$-0.61

Q4 23

+23.6%

$-0.55vs$-0.72

Q1 24

-3.3%

$-0.62vs$-0.60

Q2 24

+12.5%

$-0.42vs$-0.48

Q3 24

-21.7%

$-0.56vs$-0.46

Q4 24

-6.8%

$-0.63vs$-0.59

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 7, 2024	$-0.59	$-0.63	-6.8%	✗ MISS
Q3 2024	Aug 1, 2024	$-0.46	$-0.56	-21.7%	✗ MISS
Q2 2024	May 2, 2024	$-0.48	$-0.42	+12.5%	✓ BEAT
Q1 2024	Mar 12, 2024	$-0.60	$-0.62	-3.3%	✗ MISS
Q4 2023	Nov 2, 2023	$-0.72	$-0.55	+23.6%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.61	$-0.65	-6.6%	✗ MISS
Q2 2023	May 9, 2023	$-0.59	$-0.56	+5.1%	✓ BEAT
Q1 2023	Mar 2, 2023	$-0.63	$-0.66	-4.8%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.51	$-0.68	-33.3%	✗ MISS
Q3 2022	Aug 4, 2022	$-0.54	$-0.67	-24.1%	✗ MISS
Q2 2022	May 5, 2022	$-0.52	$-0.56	-7.7%	✗ MISS
Q1 2022	Mar 3, 2022	$-0.41	$-0.52	-26.8%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.48	$-0.38	+20.8%	✓ BEAT
Q3 2021	Aug 9, 2021	$-0.67	$-0.41	+38.8%	✓ BEAT
Q2 2021	May 10, 2021	$-0.94	$-0.84	+10.6%	✓ BEAT
Q1 2021	Mar 12, 2021	—	$-0.15	—	—
Q4 2020	Dec 31, 2020	—	$-0.60	—	—
Q2 2020	Jun 30, 2020	—	$-0.09	—	—
Q1 2020	Mar 31, 2020	—	$-0.01	—	—

Frequently Asked Questions about LBPH

What is LBPH's current stock price?

Longboard Pharmaceuticals, Inc. (LBPH) is currently trading at $59.98 per share. The stock has moved +0.00% today.

What is the analyst price target for LBPH?

The average analyst price target for LBPH is $54.75, based on 1 analyst.

What sector is Longboard Pharmaceuticals, Inc. in?

Longboard Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is LBPH's market cap?

Longboard Pharmaceuticals, Inc. has a market capitalization of $2.34 billion, making it a mid-cap company.

Does LBPH pay dividends?

No, Longboard Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.